Yes, I am. It would be nice for some of us locals to get together for a drink, even before the celebration event!
Sentiment: Strong Buy
this was trading at $9 when management decided they need money immediately...and got $7 per share for the stock that was trading at $9
investorgenius... well, young man (you have 9 years on me and I sure don't plan on being old when I'm 73!), you have been blessed (except for in the knees). AMPE is about 30% of my worth, but I fully expect it to result in a doubling or more of my worth. I have had four knee surgeries (all long after I invested in Ampio). First invested well over 10 years ago. If you're in the Denver area... let's celebrate together once this thing takes off!!
I know of at least 2 patients of Eylea/Luvestin (??) that would pay good money not to get that injection!! Small sample size but common sense prevails (pill or injection). My concern of Optina results not meeting Eylea/Luvestin' is not very big as I believe Optina will sell in the marketplace (as long as we're not drastically under-performing those drugs)
No doubt ease of use is a factor. If the benefit of injection was significantly greater (and risks equivalent) the injection may very well be preferred. Remember, local anesthetic is used and the actual procedure is not as barbaric as it sounds. It's similar to the common older (non-pressurized air) glaucoma exam with the probe(needle) being applied for 3-4 sec vs 1 sec * 3-4 times. Another factor to consider is the development of new formulations of anti-vegf biologics (and, yes, stem cells). So, competition remains a factor to my knowledge.
Androgens, particularly testosterone, have been linked to some cognitive improvement. However, the side effects of long term, high level dosing, have prevented this MOA from being actively pursued. Might be interesting to see what other medication these individuals were on and whether there is a synergestic effect. However, there are no effective AD medications currently. I am assuming that these were only mildly impaired individuals.
The inclusion of a significant number anti-VEGF non-responders is good news. Need to look at what that rate is for the total DME population. If it works here, then there is a clear niche. How it compares in performance to those current therapies over a broad population is still the bigger question. There was a difference in the scales used for reporting initial Optina results and those in the anti-VEGF trials (# letters vs categories) so 1:1 comparison is difficult to project.
Still would like to have some idea of IDRC meeting schedule, reports, and what is going on with those 1/3 that have finished the trial. But, it may be that that data is confidential and/or unknown.
th3k, Yes I have been very blessed in my life. I am 73 years old and just last Nov. had my second knee replacement. I had taken over 30 injections to my knees hoping and praying for a miracle drug to help people like me and possibly regrow cartilage in my knees. My investment in ampe represents about 10% of my net worth and I feel as you this is going to be the best investment in my 73 years on this old earth. Good luck to you.
Here's my question to you. Let's say Optina results are good but not great (not as good REGN) and we get approval from the FDA. Don't you think real world patients and their Dr's wouldn't want to try Optina (pill) 1st to see if it worked before they agree to have a needle stuck in their eye??? ANY improvement in eyesight has to be better than none. IF we get approval I think this drug sells because of the above reason
investorgenius... if you own 120K shares on AMPE at $8.40 you are financially doing pretty well already. However, I believe that in fairly short order you will be in a whole new category. I've got over 100K, but its a very big part of my total net worth. I am convinced that this stock will put me into a whole new category and change my life. If it doesn't, I'm still ok, but I think this will be the best bet I've ever made.
grindle... that's right. If I recall correctly they commented on the fact that these participants had NO other therapy at all to help them. I also recall that they said that it was the investigators at the Ampion trial sites that wanted to go to the FDA to plead for the drug - and stating that part of the reason for what could be viewed as limited WOMAC scale improvement was due to the fact that the Ampion patients started becoming much, much more active - doing things they had not been able to do before.
They also made a comment about the makeup of the Optina trial participants alluding to a large percentage (dont' recall the exact number) that had been on Eylea, REGN's drug, Luvestin (Not sure of all the names) and were not getting better on those drugs and therefore came to this trial
bill... you'd also be interested in the apparent effect of Optina on the trial participants with Alzheimer's. Apparently (if I remember correctly :) ) Alzheimer patients taking Optina showed significant improvement on their Alzheimer's testing. I think the N was only about 3 or 4, but still it was a dramatic improvement. Dr. BarOr explained how that would make sense based on Optina's MOA. Very exciting.
I hope they post the conference call soon. There was an awful lot to absorb.
Well said grindle and hope they post the recording as I am still interested in any info regarding the Optina patients that have completed treatment. Pre-approved (ie, repurposed) drugs have lower risk due to known safety profiles. Showing sufficient efficacy in new indications is still a major risk. Ampion doesn't even have that risk. Good to hear a consensus that post-spo is non-company specific.
I myself feel much better after the conference call. I was worried they were going to say something negative but only positive comments and events. Because of this to me it is clear that the stock drop is purely a result of manipulation as everyone waits for FDA approval. I agree that is always a risk but one I am willing to bet on. The fear I had that there might be bad news known by some and not others is now gone. I could care less about the daily price and now I am clear about the long term direction and timeline I feel very good about owning this stock.